<DOC>
	<DOCNO>NCT01434888</DOCNO>
	<brief_summary>The objective study investigate pharmacokinetics , safety tolerability preservative-free fixed-dose combination tafluprost 0.0015 % timolol 0.5 % ( FDC ) preservative-free tafluprost 0.0015 % timolol 0.5 % eye drop healthy volunteer .</brief_summary>
	<brief_title>Pharmacokinetics , Safety Tolerability Preservative-free Fixed Dose Combination Tafluprost 0.0015 % Timolol 0.5 % Eye Drops</brief_title>
	<detailed_description />
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Aged 18 45 year Good general health Meet best correct ETDRS visual acuity Significant systemic ocular disease History eye surgery , include refractive surgery Allergy hypersensitivity study drug Low heart rate ( &lt; 50 bpm ) Clinically relevant low blood pressure Asthma Bradycardia Use contact lens within one week prior screen study Clinically significant obesity ( body mass index &gt; 30 kg/m2 ) Blood donation within 2 month prior screen Females pregnant lactating female use adequate contraceptive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>pharmacokinetics</keyword>
</DOC>